Bainco International Investors grew its stake in shares of Danaher Co. (NYSE:DHR) by 5.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 65,233 shares of the conglomerate’s stock after buying an additional 3,256 shares during the period. Bainco International Investors’ holdings in Danaher were worth $6,196,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in DHR. Zions Bancorporation increased its position in Danaher by 118.3% during the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after buying an additional 667 shares in the last quarter. Patten Group Inc. increased its position in Danaher by 262.3% during the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after buying an additional 3,497 shares in the last quarter. First Personal Financial Services increased its position in Danaher by 128.9% during the fourth quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock worth $114,000 after buying an additional 691 shares in the last quarter. Calton & Associates Inc. purchased a new position in Danaher during the fourth quarter worth $114,000. Finally, Truewealth LLC purchased a new position in Danaher during the fourth quarter worth $121,000. 77.83% of the stock is owned by institutional investors.
In other Danaher news, insider Rainer Blair sold 3,981 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $100.05, for a total transaction of $398,299.05. Following the completion of the sale, the insider now owns 49,751 shares of the company’s stock, valued at $4,977,587.55. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP William K. Daniel sold 131,066 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $102.05, for a total value of $13,375,285.30. Following the sale, the executive vice president now directly owns 270,523 shares of the company’s stock, valued at approximately $27,606,872.15. The disclosure for this sale can be found here. In the last three months, insiders have sold 313,260 shares of company stock valued at $31,657,786. 12.20% of the stock is owned by company insiders.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.03. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The firm had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the previous year, the business earned $1.05 earnings per share. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. analysts expect that Danaher Co. will post 4.37 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Thursday, March 29th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Wednesday, March 28th. This is an increase from Danaher’s previous quarterly dividend of $0.14. Danaher’s payout ratio is 16.00%.
Several equities analysts have weighed in on DHR shares. Argus raised their price target on Danaher from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. Cowen reissued a “buy” rating and set a $110.00 price target on shares of Danaher in a research report on Tuesday, January 30th. Credit Suisse Group reissued a “neutral” rating on shares of Danaher in a research report on Friday. Robert W. Baird reissued a “buy” rating and set a $99.00 price target on shares of Danaher in a research report on Friday, December 15th. Finally, Citigroup lifted their price objective on Danaher to $107.00 and gave the company a “buy” rating in a research report on Friday, December 15th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $101.23.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.